Clinical studies have reported the benefit of adding HER-targeted drugs to an aromatase inhibitor in ER+ HER2 amplified tumours [3,37], but a potential biological role of the HER-receptor family in tumours not amplified for HER2 remains poorly understood. Here, CYP19A1 is linked to neoplasm.